
University of Florida researchers are launching a clinical trial to find out whether an experimental intravenous drug can safely slow the progression of Type 1 diabetes in people recently diagnosed with the disease. The study, led by UF's Michael Haller, is backed by a $5.5 million grant and zeroes in on patients who are still in the earliest stretch of their diagnosis, when the body's insulin-producing cells are still being destroyed.
Haller discussed the research with FOX 35's Garrett Wymer live over Zoom, as reported by FOX 35 Orlando. The grant comes from Breakthrough T1D, and according to UF Health, the trial is also supported by Miami-based SAB Biotherapeutics, the company that developed the drug being tested, called SAB-142.
How the Drug Is Supposed to Work
SAB-142 is administered intravenously, and its antibodies are designed to target T cells, the immune cells that drive the autoimmune attack on the pancreas in Type 1 diabetes, per the same UF Health account. UF Health is careful to note that the therapy is not a cure. Instead, if successful, it might slow the loss of beta cells by, in a sense, calming or reducing that immune attack.
The study, known as PRISE-hATG, is built for a narrow window: people with Stage 3 Type 1 diabetes who were diagnosed somewhere between 100 days and two years earlier, according to Breakthrough T1D. It's described as a randomized, double-blind, placebo-controlled, investigator-led study, and Breakthrough T1D says it is designed to assess whether SAB-142 can preserve endogenous C-peptide, a marker of the body's own remaining insulin production, while also modulating immune responses. SAB Biotherapeutics will co-fund the study alongside the grant.
A Companion to a Larger National Trial
Breakthrough T1D frames PRISE-hATG as complementing a bigger, already-running effort: the Phase 2b SAFEGUARD trial, which is testing SAB-142 in people with newly diagnosed Stage 3 Type 1 diabetes. ClinicalTrials.gov describes SAFEGUARD as an investigator- and participant-blinded, placebo-controlled, parallel-arm study evaluating the drug's efficacy, safety and tolerability in that new-onset population.
SAB Biotherapeutics' own business update, reported by Yahoo Finance, said the adult and adolescent cohorts in SAFEGUARD are fully enrolled and closed for screening, while pediatric patients ages 5 to 11 are still actively enrolling. The company said SAFEGUARD remains on track for full enrollment in the fourth quarter of this year, with topline data expected in the second half of 2027. That same update said the newer PRISE-hATG study expects to dose its first patient before the end of this year.
Early Data and Disclosed Ties
Earlier clinical data released by SAB Biotherapeutics in April offers a glimpse of how small this research has been so far: a Phase 1 cohort for Type 1 diabetes included just six adults, with four receiving SAB-142 at 2.5 mg/kg and two receiving a placebo, the company reported. UF Health also discloses that Haller holds equity in SAB Biotherapeutics, serves on its scientific advisory board and has received compensation from the company, a potential conflict that is laid out directly in UF Health's own announcement of the grant.









